TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The CDC’s updated 2026 Antimicrobial Resistance Threats Report lists 19 pathogens and estimates they cause 9.7 million infections and 50,800 deaths in the United States each year. Four drug-resistant pathogens remain in the agency’s top “urgent” category, while C. difficile moved down to “serious” and six pathogens joined a watch list.
The CDC’s updated 2026 Antimicrobial Resistance Threats Report identifies 19 pathogens across threat categories and estimates they cause 9.7 million infections and 50,800 deaths annually in the United States. Four drug-resistant pathogens—Candida auris, carbapenem-resistant Acinetobacter, carbapenem-resistant Enterobacterales and drug-resistant Neisseria gonorrhoeae—are classified as urgent threats, the agency’s top tier.
The report ranks pathogens as “concerning,” “serious” or “urgent,” and separately names six potential threats on a watch list. The CDC’s figures describe the combined estimated annual burden from the listed pathogens; the report summary does not attribute all 50,800 deaths to drug-resistant infections alone. The headline figure is therefore a measure of the report’s broader pathogen list, not a count of deaths caused only by the four urgent drug-resistant threats.
Among the four urgent threats, the report describes C. auris as a multidrug-resistant yeast that can cause severe infections, especially in people with serious underlying medical conditions. Reported U.S. cases rose from 48 in 2016 to 4,523 in 2023. Carbapenem-resistant Acinetobacter was linked to 9,497 U.S. hospitalizations and an estimated 817 deaths in 2023. Carbapenem-resistant Enterobacterales, which include strains of E. coli and Klebsiella, were linked to 14,878 hospitalizations and an estimated 1,252 deaths that year.
Drug-resistant gonorrhea adds a different public-health concern. The report estimates that resistant N. gonorrhoeae caused 787,000 U.S. infections in 2023; 55.4% of gonorrhea cases that year were resistant to at least one of six antibiotics or showed elevated minimum inhibitory concentrations. The CDC also moved drug-resistant N. meningitidis into the serious-threat category and added drug-resistant dermatophytes, drug-resistant Haemophilus influenzae and nontuberculous mycobacteria to the watch list.
Risks for Patients and Care
Antimicrobial resistance can make infections harder to treat and can narrow the medicines available to clinicians. Infectious Diseases Society of America president Wendy Armstrong said resistant infections can prolong hospital stays and raise health-care costs. She also warned that they may complicate care such as cancer chemotherapy, organ transplants and surgery, where preventing or treating infection is part of managing risk.
The categories also point to distinct settings and populations at risk. The report notes that carbapenem-resistant Acinetobacter is a particular concern in hospitals and nursing homes, where contaminated surfaces or equipment can spread infection. Patients with ventilators or catheters, and people receiving longer courses of antibiotics, face greater risk from carbapenem-resistant Enterobacterales. These details matter to patients and care teams because the report is not only a ranking: it identifies pathogens for which prevention, surveillance and treatment options warrant attention.
The figures should not be read as a prediction that any individual will become infected. They are national estimates for the pathogens covered, and the risks vary by organism, health status and care setting. The report’s change in C. difficile’s category also shows that threat levels can shift as infection patterns and prevention measures change.
Products Worth Considering
Levoit Eleva 300X HEPA Air Purifier for Home and Bedroom
Garmin Forerunner 570 GPS Running Smartwatch, 47mm, Aluminum, Black
Garmin Venu 3 Fitness Smartwatch, 45 mm, Black
As an affiliate, we earn on qualifying purchases.
How the Threat List Changed
The CDC’s report updates its assessment of antimicrobial-resistant pathogens, placing them in threat categories and identifying potential emerging concerns separately on a watch list. This year, C. difficile moved from urgent to serious. The report attributes the change in part to successful infection-prevention measures and declining case numbers since 2011; it does not say the infection is no longer a significant concern.
The watch list is for pathogens whose disease burden remains uncertain but could become a public-health threat. The additions include drug-resistant dermatophytes and H. influenzae, as well as nontuberculous mycobacteria. Drug-resistant N. meningitidis, meanwhile, was categorized as a serious threat requiring prompt and sustained action.
For gonorrhea, the source report notes that the FDA approved gepotidacin, marketed as Blujepa, and zoliflodacin, marketed as Nuzolvence, in 2025 as new antibiotics for the infection. Their approvals add treatment options, but the CDC’s resistance estimates show why continued monitoring remains relevant.
“These numbers are alarming by any measure, but they are particularly sobering when infectious diseases physicians connect real patients with these statistics in their everyday experience.”
— Wendy Armstrong, president of the Infectious Diseases Society of America
Limits of the Estimates
The report summary gives a combined estimate of 9.7 million infections and 50,800 deaths per year, but the source material does not specify the exact estimation period for those annual totals or provide a breakdown of the deaths by pathogen in that summary. The separate hospitalization and death figures for Acinetobacter and Enterobacterales are for 2023 and should not be treated as the same measure as the overall annual estimates.
The watch-list pathogens are described as having an uncertain disease burden. The source material does not provide estimates of how many infections or deaths they cause, nor does it detail the methods behind each estimate or the criteria used to move pathogens between categories. The report’s findings also do not establish how much of any individual patient’s risk is attributable to a listed pathogen.
It remains unclear from the material available whether Congress will advance the PASTEUR Act, which Armstrong supports. Both versions of the bill remain stalled in congressional committees, according to the report.
Surveillance and Policy Steps
Health agencies and medical organizations will continue tracking resistant infections and the pathogens added to the watch list. The CDC’s report gives a current snapshot of threat categories, while the source material does not specify a date for the next update. Future surveillance can clarify whether the case burden changes and whether watch-list organisms warrant a higher threat classification.
Armstrong called for passage of the PASTEUR Act, which would create a federal program to support development of antimicrobial drugs targeting the most threatening pathogens and infections. The bill’s next step is uncertain: both versions remain in committee, and no timetable for further action is provided. The report also points to approved newer antibiotics for gonorrhea, while ongoing resistance monitoring will be needed to understand their role against changing strains.
Key Questions
Does the CDC say drug-resistant superbugs alone kill 50,800 Americans each year?
No. The report estimates that the full group of listed pathogens causes 9.7 million infections and 50,800 deaths annually. The source summary does not say that all those deaths are due solely to drug-resistant infections or provide a complete breakdown by pathogen.
Which pathogens are in the CDC’s urgent category?
The four urgent drug-resistant pathogens named in the report are Candida auris, carbapenem-resistant Acinetobacter, carbapenem-resistant Enterobacterales and drug-resistant Neisseria gonorrhoeae.
Why did C. difficile move to a lower threat category?
The report says C. difficile moved from urgent to serious, in part because infection-prevention measures have been successful and case numbers have declined since 2011. It remains listed as a serious threat.
What is the CDC’s watch list?
It identifies potential threats for which the disease burden is uncertain but could become a public-health concern. The updated list includes drug-resistant dermatophytes, drug-resistant Haemophilus influenzae and nontuberculous mycobacteria.
Source: medpagetoday.com
